Tuesday, June 30, 2020 8:19:47 AM
But it doesn't change the fact that CLR-131 is a very interesting candidate with some very exiting trial results.
Just revisited their lates clinical presentation and think it is good news all around.
Just the fact that the MOA of CLR-131 is unique makes it relevant in later lines.
I look forward to the Clover-1 trial that will hopefully readout beginning of Q3. Strongly believe that the 2-cycle dosing will show solid results.
Also looking forward to update on phase I Pediatric Brain & Solid Tumors.
Recent CLRB News
- Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 08/26/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:15:38 PM
- Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq • GlobeNewswire Inc. • 08/23/2024 09:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:15:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:45:19 AM
- Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 08/13/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:47 PM
- UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 09:15:14 PM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2024 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 10:45:24 AM
- Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months • GlobeNewswire Inc. • 07/23/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:45:16 AM
- Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million • GlobeNewswire Inc. • 07/22/2024 10:40:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:15:21 PM
- Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape • GlobeNewswire Inc. • 06/27/2024 10:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:17 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM